# An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients

> **NCT00576173** · PHASE4 · COMPLETED · sponsor: **Johnson & Johnson Taiwan Ltd** · enrollment: 60 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** tramadol hydrochloride; acetaminophen

## Key facts

- **NCT ID:** NCT00576173
- **Lead sponsor:** Johnson & Johnson Taiwan Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** —
- **Final completion:** 2007-02
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2010-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00576173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00576173, "An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00576173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*